2030 Clinical Development Licensing 
Drug Discovery World
MAY 6, 2024
Professor Dr Carla van Gils, Director of KWF, comments: “Many of academia’s most innovative agents can be difficult to bring into clinical development. Partnering with the Centre for Drug Development enables us to jump into the bench-to-bedside gap and fast track academic findings into clinical trials. billion ($7.9
LifeSciVC
JANUARY 16, 2024
These are incredible forecasts and CAGRs, which if we assume directionally correct, rely not only on steady growth for approved therapies but also a substantial success rate of, and continued investment in, the development pipeline. recent announcements from Merck and Sanofi for obesity and broader metabolic disease). Join the club.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
The Pharma Data
MARCH 2, 2021
Boehringer Ingelheim and Gubra today announced a new research and licensing agreement focused on the identification and validation of targets and innovative peptide compounds for the treatment of obesity. ii It is projected that by 2030, close to half of the U.S. NASH and type 2 diabetes, as well as for a number of cancers.
The Pharma Data
AUGUST 5, 2021
The platform already has potentially ground-breaking medical innovations in clinical development, such as a therapy for the treatment of Parkinson’s. Earnings were also diminished by a negative product mix, currency effects of 111 million euros, and the later receipt of license revenues. percent (Fx & portfolio adj.)
The Pharma Data
NOVEMBER 5, 2020
Key Pipeline Progress Regeneron has more than 20 product candidates in clinical development, including five marketed products for which it is investigating additional indications. Updates from the clinical pipeline include: Dupixent ® (dupilumab). R&D: Up-front payments related to license and collaboration agreements. (85).
Expert insights. Personalized for you.
147 
Let's personalize your content